TOBRADEX (tobramycin and dexamethasone) by Novartis is corticosteroid hormone receptor agonists [moa]. Approved for aminoglycoside antibacterial [epc]. First approved in 1988.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
TOBRADEX is a fixed-dose ophthalmic ointment combining tobramycin (aminoglycoside antibiotic) and dexamethasone (corticosteroid) for topical ocular use. It treats bacterial eye infections with concurrent inflammation by simultaneously eliminating bacteria and reducing inflammatory response. The combination addresses both infectious and inflammatory components of ocular disease.
Product approaching loss of exclusivity with minimal Medicare claims signals end-of-life commercial trajectory; brand teams should expect resource consolidation and transition planning.
Corticosteroid Hormone Receptor Agonists
Aminoglycoside Antibacterial
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis
Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis
TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension
Zylet vs TobraDex in Blepharokeratoconjunctivitis
Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle
Worked on TOBRADEX at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on TOBRADEX offers limited upside given LOE Approaching status; roles are primarily defensive and focused on margin protection and generic transition planning. Career growth on this product is constrained; professionals should view it as a consolidation or maintenance role rather than a launchpad for advancement.